Concepedia

Changnian Liu

CL

Statistics

Publications

9

Citations

759

H-Index

9

Active since

1992

Affiliations

Incyte (United States)(Current)

Experimental Station

University of Kansas

University of Kansas Medical Center

Changnian Liu is an author at Incyte (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

1992–2013

9

Publications

9

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Bin-Bing Zhou, Michael Peyton, Biao He et al. · Cancer Cell · 2006 · 375 citations · Full text

, , +11

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model

Eddy W. Yue, Brent Douty, Brian Wayland et al. · Journal of Medicinal Chemistry · 2009 · 217 citations · Full text

, , +9

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

Xiangdong Liu, Jordan S. Fridman, Qian Wang et al. · Cancer Biology & Therapy · 2006 · 56 citations · Full text

, , +17

Discovery of a Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor for the Treatment of Cancer

Wenqing Yao, Jin‐Cong Zhuo, David Burns et al. · Journal of Medicinal Chemistry · 2007 · 33 citations · Full text

, , +17

The development of antibody delivery systems to target cancer with highly potent maytansinoids

Changnian Liu, Ravi Chari · Expert Opinion on Investigational Drugs · 1997 · 24 citations

, , +17

1–5 of 9